12:00 AM
Aug 11, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glycogen synthase kinase 3β (GSK3B); ubiquitin specific peptidase 22 (USP22); lysine-specific demethylase 1 (LSD1; KDM1A)


INDICATION: Brain cancer

Patient sample and mouse studies suggest that inhibiting the GSK3β-USP22-LSD1 axis could help treat glioblastoma multiforme (GBM) and other brain cancers. In tumor samples from GBM and astrocytoma patients, levels of GSK3β, USP22 and LSD1 correlated with tumor grade. In an orthotopic xenograft mouse...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >